Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720840 | 0.73 | — | — | |
| SCHEMBL308136 | 0.71 | MPO (0.36) | MPO | |
| SCHEMBL4774365 | 0.68 | MPO (0.34) | MPO | |
| SCHEMBL563036 | 0.64 | MPO (0.32) | MPO | |
| SCHEMBL7617970 | 0.60 | MPO (0.41) | MPO | |
| SCHEMBL28887357 | 0.60 | — | — | |
| SCHEMBL2523527 | 0.59 | DHFR (0.34) | — | |
| SCHEMBL6904577 | 0.59 | MPO (0.36) | MPO | |
| SCHEMBL4076427 | 0.59 | MPO (0.36) | MPO | |
| SCHEMBL8662289 | 0.59 | MPO (0.36) | MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3761989-B1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB ABC LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-112351781-B | Imidazodiazepine diketones and methods of use thereof | 金翅雀生物公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230365575-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-11-16 | — | — | US | disclosed |
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2006-10-26 | — | — | US | disclosed |
| EP-1227103-B1 | Ring-expanded nucleosides and nucleotides | NABI (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2004-04-22 | — | — | US | disclosed |
| EP-0724587-B1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | NABI (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1227103-A2 | Ring-expanded nucleosides and nucleotides | Nabi (US) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365575-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | REN, ATP6V1B1, GLS | MPO 1497/4885 |
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | PNP, UMPS, ADA | MPO 4127/4885 |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | PNP, PAICS, UMPS | MPO 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.